Ascendis Pharma A (ASND) Tax Provisions (2014 - 2026)
Ascendis Pharma A (ASND) posted Tax Provisions of $793.2 million for Q1 2026, up 10037.54% sequentially from -$8.0 million in Q4 2025, and up 71172.03% YoY from N/an in Q1 2025.
Ascendis Pharma A (ASND) Tax Provisions (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Tax Provisions for 13 years, with the latest figure at $793.2 million in Q1 2026.
- Quarterly Tax Provisions rose 71172.03% year-over-year to $793.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $776.6 million (up 21422.79% YoY) and the FY2025 annual result came in at $46.2 million, up 992.78% from the prior year.
- Tax Provisions improved to $793.2 million in Q1 2026 per ASND's latest filing, from -$8.0 million in the prior quarter.
- Over five years, Tax Provisions peaked at $793.2 million in Q1 2026 and troughed at -$8.0 million in Q4 2025.
- A 5-year average of $44.6 million and a median of -$1.1 million in 2024 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2022 and 2026: Tax Provisions tumbled 4083.86% in 2022, then jumped 71172.03% in 2026.
- Over 5 years, Tax Provisions stood at -$5.5 million in 2022, then decreased by 14.19% to -$6.2 million in 2023, then jumped by 81.39% to -$1.2 million in 2024, then slumped by 588.43% to -$8.0 million in 2025, then surged by 10037.54% to $793.2 million in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $793.2 million, -$8.0 million, and -$4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 793.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 793.20 Mn |
| Dec 31, 2025 | -7.98 Mn |
| Sep 30, 2025 | -4.23 Mn |
| Jun 30, 2025 | -4.36 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | -1.16 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Jun 30, 2024 | -246,607.25 |
| Mar 31, 2024 | -2.72 Mn |
| Dec 31, 2023 | -6.23 Mn |
| Sep 30, 2023 | -702,140.86 |
| Jun 30, 2023 | 467,148.56 |
| Mar 31, 2023 | -1.39 Mn |
| Dec 31, 2022 | -5.46 Mn |
| Sep 30, 2022 | 168,381.81 |
| Jun 30, 2022 | 50,151.66 |
| Mar 31, 2022 | 270,483.39 |
| Dec 31, 2021 | -130,412.69 |
| Sep 30, 2021 | 5,896.44 |
| Jun 30, 2021 | -81,890.46 |